Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to McDermott, David
Item TypeName
Academic Article Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.
Academic Article Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials.
Academic Article Plasma cell problems: Case 1. Disseminated cutaneous plasmacytomas treated with total skin electron radiotherapy.
Academic Article A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma.
Academic Article Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer.
Academic Article Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion.
Academic Article Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses.
Academic Article Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of response.
Academic Article Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma.
Academic Article Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.
Academic Article Immunotherapy of metastatic renal cell carcinoma.
Academic Article Management of metastatic renal cell carcinoma in patients with poor prognosis.
Academic Article Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.
Academic Article Improved survival with ipilimumab in patients with metastatic melanoma.
Academic Article Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.
Academic Article Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: results from a medical chart review study.
Academic Article Immunotherapy for metastatic renal cell carcinoma.
Academic Article Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference.
Academic Article Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy.
Academic Article Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma.
Academic Article Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.
Academic Article Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak.
Academic Article Case records of the Massachusetts General Hospital. Case 17-2008. A 63-year-old man with metastatic renal-cell carcinoma.
Academic Article The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.
Academic Article Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
Academic Article Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial.
Academic Article Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Academic Article Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma.
Academic Article Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review.
Academic Article A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
Academic Article Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy.
Academic Article Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma.
Academic Article Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
Academic Article Update on the application of interleukin-2 in the treatment of renal cell carcinoma.
Academic Article Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
Academic Article Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
Academic Article The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy.
Academic Article Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
Academic Article Addition of gemcitabine at the time of sunitinib resistance in metastatic renal cell cancer.
Academic Article Immunotherapy for renal cell carcinoma.
Academic Article What is standard initial systemic therapy in metastatic renal cell carcinoma?
Academic Article Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference.
Academic Article Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
Academic Article Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.
Academic Article Application of IL-2 and other cytokines in renal cancer.
Academic Article More support for the judicious use of high-dose interleukin-2 in patients with advanced melanoma.
Academic Article Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group study.
Academic Article Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma.
Academic Article Designing clinical trials for kidney cancer based on newly developed prognostic and predictive tools.
Academic Article Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma.
Academic Article Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma.
Concept Breast Neoplasms
Concept Immunotherapy, Adoptive
Concept Urogenital Neoplasms
Concept Colorectal Neoplasms
Concept Cancer Vaccines
Concept Kidney Neoplasms
Concept Immunotherapy
Concept Brain Neoplasms
Concept Lung Neoplasms
Concept Skin Neoplasms
Concept Neoplasms
Concept Urologic Neoplasms
Concept Prostatic Neoplasms
Concept Adrenal Gland Neoplasms
Concept Uveal Neoplasms
Concept Urinary Bladder Neoplasms
Academic Article Immunotherapy and targeted therapy combinations in renal cancer.
Academic Article A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802.
Academic Article Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program.
Academic Article Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha.
Academic Article Immunotherapy of metastatic renal cell carcinoma.
Academic Article Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.
Academic Article Novel immunotherapies in GU malignancies.
Academic Article Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma.
Academic Article The application of high-dose interleukin-2 for metastatic renal cell carcinoma.
Academic Article Improving the therapeutic index of IL-2.
Academic Article BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.
Academic Article The high-dose aldesleukin (IL-2) "select" trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma.
Academic Article Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial data.
Academic Article Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma.
Academic Article Immune checkpoint inhibitors as novel targets for renal cell carcinoma therapeutics.
Academic Article Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies.
Academic Article The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.
Academic Article Immune therapy for kidney cancer: a second dawn?
Academic Article A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study.
Academic Article FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer.
Academic Article PD-1 as a potential target in cancer therapy.
Academic Article A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States.
Academic Article The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium.
Academic Article Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
Academic Article Potential of new therapies like anti-PD1 in kidney cancer.
Academic Article Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors.
Academic Article Bevacizumab plus ipilimumab in patients with metastatic melanoma.
Academic Article Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape.
Academic Article Interferon, interleukin-2, and other cytokines.
Academic Article Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.
Academic Article Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma.
Academic Article Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Academic Article The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.
Academic Article Nivolumab for the treatment of cancer.
Academic Article Cytotoxic T-lymphocyte antigen-4 blockade in melanoma.
Academic Article Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.
Academic Article The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Academic Article Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
Academic Article BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).
Academic Article Emerging role for novel immunotherapy agents in metastatic renal cell carcinoma: from bench to bedside.
Academic Article Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
Academic Article Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes.
Academic Article The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2).
Academic Article Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.
Academic Article Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic Nodes.
Academic Article Vascular and Metabolic Implications of Novel Targeted Cancer Therapies: Focus on Kinase Inhibitors.
Academic Article Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma.
Academic Article Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma.
Academic Article Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma.
Academic Article Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
Academic Article Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma.
Academic Article Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review.
Academic Article Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.
Academic Article Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study.
Academic Article Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.
Academic Article Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Academic Article Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
Academic Article A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies.
Academic Article Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma.
Academic Article Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma.
Grant DF/HCC Kidney Cancer SPORE
Academic Article A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma.
Academic Article Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody.
Academic Article Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases.
Academic Article VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma.
Academic Article Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma.
Academic Article Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2.
Academic Article FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma.
Academic Article Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma.
Academic Article Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma.
Academic Article Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.
Academic Article Clinical Trial Design and Endpoints for Stage IV Melanoma in the Modern Era.
Academic Article Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM.
Academic Article Impact of integrated palliative care model on end-of-life (EOL) quality metrics for patients with kidney cancer (RCC) and melanoma (M).
Academic Article Integrating palliative care into care of patients with kidney cancer and melanoma.
Academic Article CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma.
Academic Article Developing a model for embedded palliative care in a cancer clinic.
Academic Article Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025.
Academic Article Combined Anti-VEGF and Anti-CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes.
Academic Article Improving End-of-Life Care: Palliative Care Embedded in an Oncology Clinic Specializing in Targeted and Immune-Based Therapies.
Academic Article A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status.
Academic Article Combined blockade of vascular endothelial growth factor and programmed death 1 pathways in advanced kidney cancer.
Academic Article Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.
Academic Article Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.
Academic Article Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry.
Academic Article Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study.
Academic Article Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events.
Academic Article Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.
Academic Article Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.
Academic Article Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.
Academic Article Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Academic Article Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma.
Academic Article An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.
Academic Article Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.
Academic Article Combinations of Bevacizumab With Immune Checkpoint Inhibitors in Renal Cell Carcinoma.
Academic Article Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma.
Academic Article Clinicopathologic features correlated with paradoxical outcomes in stage IIC versus IIIA melanoma patients.
Academic Article An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma.
Academic Article Sequential treatment approaches in  the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis.
Academic Article Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma.
Academic Article Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.
Academic Article NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma.
Academic Article Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.
Academic Article Progress in Kidney Cancer Outcomes Through Collaboration, Innovation, and Discovery.
Academic Article Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma.
Academic Article irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.
Academic Article Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.
Academic Article Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.
Academic Article Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison.
Academic Article Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.
Grant Developing a Translation Pipeline for VHL Mutant Malignancies
Academic Article The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?
Academic Article Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?
Academic Article Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.
Academic Article To treat or not to treat: Patient exclusion in immune oncology clinical trials due to preexisting autoimmune disease.
Academic Article Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab.
Academic Article Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab.
Academic Article Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma.
Academic Article Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Academic Article Vascular endothelial growth factor and programmed death-1 pathway inhibitors in renal cell carcinoma.
Academic Article Metabolomic adaptations and correlates of survival to immune checkpoint blockade.
Academic Article Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features.
Academic Article Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.
Academic Article The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC).
Academic Article Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma.
Academic Article Checkpoint inhibitor immunotherapy in kidney cancer.
Academic Article Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma.
Academic Article Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma.
Academic Article High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade.
Academic Article Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma.
Academic Article Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma.
Academic Article Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.
Academic Article Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma.
Academic Article Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial.
Academic Article Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma.
Academic Article Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.
Academic Article Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20).
Search Criteria
  • Cancer
  • immunotherapy
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.